Jochen G. Salfeld
33Patents
24h-index
58Co-inventors
88Inventor score
Filing activity: Jun 14, 1994 → Apr 8, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6090382A | Human antibodies that bind human TNF.alpha. | Emerging Cross-Sectional Technologies | 444 | Expired |
| US7612181B2 | Dual variable domain immunoglobulin and uses thereof | Emerging Cross-Sectional Technologies | 343 | Active |
| US6258562A | Human antibodies that bind human TNF.alpha. | Emerging Cross-Sectional Technologies | 307 | Expired |
| US6914128B1 | Human antibodies that bind human IL-12 and methods for producing | Chemistry; Metallurgy | 292 | Expired |
| US6509015B1 | Human antibodies that bind human TNFa | Emerging Cross-Sectional Technologies | 211 | Expired |
| US8258268B2 | Dual variable domain immunoglobulin and uses thereof | Emerging Cross-Sectional Technologies | 164 | Active |
| US7223394B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 160 | Expired |
| US7541031B2 | Methods for treating rheumatoid arthritis using human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 147 | Active |
| US7588761B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 143 | Expired |
| US5650298A | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters | Chemistry; Metallurgy | 97 | Expired |
| US8414894B2 | Human antibodies that bind human TNFα and methods of using same | Emerging Cross-Sectional Technologies | 73 | Active |
| US8206714B2 | Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa | Emerging Cross-Sectional Technologies | 72 | Active |
| US8197813B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 71 | Active |
| US8372401B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 70 | Active |
| US8372400B2 | Methods of treating disorders using human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 69 | Active |
| US8722855B2 | Dual variable domain immunoglobulins and uses thereof | Chemistry; Metallurgy | 64 | Active |
| US7504485B2 | Human antibodies that bind human IL-12 | Chemistry; Metallurgy | 62 | Expired |
| US7883704B2 | Methods for inhibiting the activity of the P40 subunit of human IL-12 | Chemistry; Metallurgy | 62 | Active |
| US8753633B2 | Human antibodies that bind human TNFα | Emerging Cross-Sectional Technologies | 49 | Active |
| US7767207B2 | Antibodies that bind IL-18 and methods of inhibiting IL-18 activity | Chemistry; Metallurgy | 46 | Expired |
| US5922927A | Methods for producing tetracycline-regulated transgenic mice | Chemistry; Metallurgy | 35 | Expired |
| US5888981A | Methods for regulating gene expression | Chemistry; Metallurgy | 30 | Expired |
| US9046513B2 | Dual variable domain immunoglobulins and uses thereof | Emerging Cross-Sectional Technologies | 26 | Active |
| US5859310A | Mice transgenic for a tetracycline-controlled transcriptional activator | Chemistry; Metallurgy | 25 | Expired |
| US6252136A | Transgenic organisms having tetracycline-regulated transcriptional regulatory systems | Chemistry; Metallurgy | 20 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.